While Parrish and her company are still anxiously waiting for full results, initial results are now starting to come in and they’re looking pretty damn good!
“This data first and foremost implies that these therapies are likely safe in humans, which was our primary concern. Additionally, it also reveals potentially beneficial metabolic changes that may conform to previous research findings. These trends may become more significant following further confirmation as we continuously monitor my biomarkers, but we are certainly encouraged by the results we have seen so far.”
– Elizabeth Parrish, CEO
Photo Credit: BioViva
These are all signs of a clear increase in metabolic health. When you couple in signs of lowered blood triglycerides, it would appear that Parrish’s cardiovascular health is also showing steady improvements with no detrimental effects thus far.
Whether or not these are the results of the biotech company’s dual gene therapies – consisting of a myostatin inhibitor and telomerase inducer – is yet to be known, but if they are, BioViva is in the midst of a huge breakthrough!
If BioViva is successful with their anti-aging gene therapy research, we could be on the brink of a major medical revolution – one which consists of finally putting an end to aging for good. Of course, like most of anything in regards to science, we first need results with plenty of evidence to verify them. If it can survive scientific scrutiny, all of us could potentially benefit from such a massive disruption in the health industry. And if it doesn’t, then it’s right back to the drawing board. Either way, it doesn’t appear that this biotech company is going to stop until they finally discover the “fountain of youth.” For which, we wish them the best of luck!